Financial Performance - The total revenue for the year ended June 30, 2025, was HKD 377,168,000, representing a 1% increase from HKD 370,069,000 in the previous year[2] - Gross profit for the same period was HKD 36,004,000, up from HKD 34,181,000, indicating a growth of 5%[2] - The net loss for the year was HKD 10,701,000, a significant improvement compared to a net loss of HKD 65,707,000 in the prior year, reflecting a reduction of approximately 84%[2] - The company's basic and diluted loss per share improved to HKD (8.43) from HKD (25.78) year-over-year[2] - The group reported a net loss of approximately HKD 14,623,000 for the year ending June 30, 2025, compared to a net loss of approximately HKD 44,212,000 for the previous year, indicating an improvement in financial performance[32] - The company reported a loss attributable to owners of approximately HKD 14.6 million for the year ending June 30, 2025, an improvement from a loss of HKD 44.2 million in the previous year[48] Assets and Liabilities - Total assets as of June 30, 2025, amounted to HKD 214,655,000, compared to HKD 209,498,000 in the previous year, showing a slight increase[4] - Current liabilities increased to HKD 277,308,000 from HKD 253,847,000, indicating a rise of approximately 9%[5] - The total accounts receivable amounted to HKD 31,908,000 as of June 30, 2025, down from HKD 34,945,000 in the previous year, with a net accounts receivable of HKD 28,787,000 after deducting provisions for losses[34] - As of June 30, 2025, the group's total liabilities were approximately HKD 178.0 million, an increase from HKD 135.9 million the previous year[51] - The net current liabilities were approximately HKD 170.5 million, compared to HKD 139.4 million as of June 30, 2024[51] - The company’s net debt to total assets ratio was approximately 79.9%, up from 63.8% the previous year[51] Cash Flow and Financial Stability - The company's cash and cash equivalents rose to HKD 6,558,000 from HKD 2,161,000, marking a significant increase of 204%[4] - The group recognized a foreign exchange gain of HKD 1,000 from overseas operations, contrasting with a loss of HKD 72 in the previous year[3] - The board believes that the group will have sufficient cash resources to meet its operational and financing needs within the next twelve months from the announcement date, thus justifying the preparation of financial statements on a going concern basis[10] - The group had a total of approximately HKD 20.3 million in assets pledged as collateral for bank borrowings as of June 30, 2025[54] - The company has implemented measures to ensure financial stability, including obtaining loans from the ultimate holding company and closely monitoring administrative expenses[56] Operational Highlights - The group plans to pursue strategic acquisitions to capture new business opportunities in the mainland China market and strengthen its revenue and profitability fundamentals[12] - The group is actively negotiating with potential investors to raise sufficient funds through financing arrangements[11] - The group has reduced its workforce to 61 employees as of June 30, 2025, down from 140 employees the previous year[57] - No significant acquisitions or disposals of subsidiaries occurred during the year ending June 30, 2025[58] - The company has not engaged in any purchase, sale, or redemption of its listed securities during the year ending June 30, 2025[59] Expenses and Costs - Sales expenses increased by approximately 13.3%, rising from HKD 12.4 million to HKD 14.1 million[45] - Administrative expenses slightly increased by about 2.6%, from HKD 20.3 million to HKD 20.8 million[46] - The group’s research and development expenses were HKD 1,610,000 for the year ending June 30, 2025, compared to HKD 2,719,000 in the previous year, indicating a reduction in R&D investment[31] - The group recognized an impairment loss of approximately HKD 1.7 million for non-current assets, significantly reduced from HKD 58.1 million in the previous year[47] Governance and Reporting - The board has resolved not to recommend the payment of a final dividend for the year ending June 30, 2025[55] - The company has adopted the corporate governance code as per the listing rules, with some deviations noted[61] - The audit committee has reviewed the annual results for the year ending June 30, 2025, in conjunction with the external auditor[66] - The company will publish its annual report containing all information required by listing rules at an appropriate time[68] - The board expresses gratitude to all employees and management for their contributions during the year[69] - The board members include executive director Lin Jia Jun (Chairman and CEO) and independent non-executive directors Huang Bao Qiang, Wang Zi Niu, and Xu Hui Ling[70]
玮俊生物科技(00660) - 2025 - 年度业绩